Frequency, diagnosis, and pharmacological treatment of giant cell arteritis in Germany: database analysis of medical insurance data

Background: For giant cell arteritis (GCA), a north-south gradient in incidence and prevalence has been described, peaking in Scandinavia. Objective: This analysis aimed to obtain up-to-date, representative data on the prevalence and incidence of GCA in Germany, updating the old, regional information on low incidence and prevalence rates. Design: Cross-sectional analysis using a large German health insurance database. Methods: This study is based on a cross-sectional analysis of claims data from the InGef (Institute for Health Research Berlin GmbH) research database, which includes a representative sample of 4.8 million insured individuals. Individuals aged ⩾50 years with continuous insurance coverage for a 3-year baseline period and the subsequent 2 years for longitudinal analysis were included. Estimates were standardised and projected to the German population. Results: Each year from 2018 to 2021, 1.7 million insured individuals met the inclusion and exclusion criteria. Extrapolated to the German population ⩾50 years in 2021, the incidence was 24/100,000, and the prevalence was 146/100,000. Diagnosis was made predominantly in outpatient settings by general practitioners (GP, 31.9%) and internists (19.5%), followed by rheumatologists (13.1%) and ophthalmologists (5.7%). Within 2 years, 16.3% of incident patients were referred to rheumatologists for treatment after diagnosis. Treatment was most commonly initiated by GPs (45.8%), followed by rheumatologists (36.1%), and included glucocorticoids (88.2%), methotrexate (26.7%), and tocilizumab (14.1%). Most common comorbidities of prevalent patients comprised arterial hypertension (77.2%), dyslipidaemia (55.0%), diabetes mellitus (28.8%), osteoporosis (34.6%), and cataract (31.2%). Conclusion: Contrary to previous reports, Germany has higher incidence and prevalence rates of GCA than previously assumed. Only approximately one-third of the incident patients were initially treated by rheumatologists. Comorbidities such as diabetes or cardiovascular diseases were common.

Authors

Institutions

Publication Details

Journal
Therapeutic Advances in Musculoskeletal Disease
Published
2026-05-01
DOI
https://doi.org/10.1177/1759720x261439725
Primary Topic
Vasculitis and related conditions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Frequency, diagnosis, and pharmacological treatment of giant cell arteritis in Germany: database analysis of medical insurance data

Nils Venhoff, Paul Ludwig, Stephanie Terner, Marco Alibone et al.
Therapeutic Advances in Musculoskeletal Disease
Vasculitis and related conditions
article

Frequency, diagnosis, and pharmacological treatment of giant cell arteritis in Germany: database analysis of medical insurance data

Nils Venhoff, Paul Ludwig, Stephanie Terner, Marco Alibone, Dominik Obermüller, Franziska Karl, Wolfgang A. Schmidt
article en

Abstract

Background: For giant cell arteritis (GCA), a north-south gradient in incidence and prevalence has been described, peaking in Scandinavia. Objective: This analysis aimed to obtain up-to-date, representative data on the prevalence and incidence of GCA in Germany, updating the old, regional information on low incidence and prevalence rates. Design: Cross-sectional analysis using a large German health insurance database. Methods: This study is based on a cross-sectional analysis of claims data from the InGef (Institute for Health Research Berlin GmbH) research database, which includes a representative sample of 4.8 million insured individuals. Individuals aged ⩾50 years with continuous insurance coverage for a 3-year baseline period and the subsequent 2 years for longitudinal analysis were included. Estimates were standardised and projected to the German population. Results: Each year from 2018 to 2021, 1.7 million insured individuals met the inclusion and exclusion criteria. Extrapolated to the German population ⩾50 years in 2021, the incidence was 24/100,000, and the prevalence was 146/100,000. Diagnosis was made predominantly in outpatient settings by general practitioners (GP, 31.9%) and internists (19.5%), followed by rheumatologists (13.1%) and ophthalmologists (5.7%). Within 2 years, 16.3% of incident patients were referred to rheumatologists for treatment after diagnosis. Treatment was most commonly initiated by GPs (45.8%), followed by rheumatologists (36.1%), and included glucocorticoids (88.2%), methotrexate (26.7%), and tocilizumab (14.1%). Most common comorbidities of prevalent patients comprised arterial hypertension (77.2%), dyslipidaemia (55.0%), diabetes mellitus (28.8%), osteoporosis (34.6%), and cataract (31.2%). Conclusion: Contrary to previous reports, Germany has higher incidence and prevalence rates of GCA than previously assumed. Only approximately one-third of the incident patients were initially treated by rheumatologists. Comorbidities such as diabetes or cardiovascular diseases were common.

Therapeutic Advances in Musculoskeletal DiseaseVol. 18
University Medical Center Freiburg (DE), Novartis (Germany) (DE), Krankenhaus Waldfriede (DE), Institute for Applied Economic Research (DE)
Reduced inequalities
Openalex Percentile: Top 12%
Vasculitis and related conditions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.